Search Results - "Fontana, Eloise"

Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer by FONTANA, Andrea, GALLI, Luca, ANTONUZZO, Andrea, D'ARCANGELO, Manolo, DANESI, Romano, DEL TACCA, Mario, FALCONE, Alfredo, BOCCI, Guido, FIORAVANTI, Anna, ORLANDI, Paola, GALLI, Costanza, LANDI, Lorenza, BURSI, Simona, ALLEGRINI, Giacomo, FONTANA, Eloise, DI MARSICO, Roberta

“…Purpose: The aims of the present study were to evaluate the clinical activity and the pharmacodynamic profile of the novel schedule of a single i.v. standard…”
Get full text

Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study by Lencioni, M, Falcone, A, Allegrini, G, Pfanner, E, Masi, G, Brunetti, I, Di Marsico, R, Fontana, E, Orlandini, C, Stampino, C G, Bartolozzi, C, Conte, P F

“…Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to…”
Get more information

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma by Loupakis, Fotios, Masi, Gianluca, Fornaro, Lorenzo, Vasile, Enrico, Allegrini, Giacomo, Fontana, Eloise, Granetto, Cristina, Salvatore, Lisa, Mentuccia, Lucia, Andreuccetti, Michele, Cortesi, Enrico, Merlano, Marco, Cascinu, Stefano, Falcone, Alfredo

“…Purpose 5-Fluorouracil (5-FU) plus cisplatin (C) can be considered a standard option for advanced gastric cancer (AGC). Irinotecan (Ir) and docetaxel (D) are…”
Get full text